3-MeO-PCMo
3-MeO-PCMo is a novel arylcyclohexylamine dissociative research chemical, a morpholine-ring PCP analogue bearing a 3-methoxy group. It is reported as notably weaker and longer-acting than related dissociatives, with no clinical study and essentially no human toxicology.
01 Overview
3-MeO-PCMo replaces the piperidine of PCP with a morpholine ring and adds a 3-methoxy substituent. Anecdotally it is described as a milder, longer, more sedating dissociative, requiring larger doses than 3-MeO-PCP or 3-MeO-PCE.
As with the rest of this family, there are no controlled human studies. Its lower potency does not make it safe: purity, exact dose-response and organ toxicity are all unknown, and it shares the bladder and dependence concerns of the broader dissociative class.
02 Mechanism
Non-competitive NMDA receptor antagonist of the PCP class; morpholine substitution lowers potency relative to piperidine analogues.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal (unverified) | 40–120 mg | Oral | Anecdotal only; described as weaker and longer than 3-MeO-PCP. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Sedating dissociationMild, long-lasting dissociation with pronounced sedation reported by users. | unquantified | Anecdotal | |
| AnalgesiaBody numbing typical of dissociatives, reported anecdotally. | unquantified | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Prolonged sedation / motor impairmentLong duration can leave users impaired for many hours. | Moderate | Unknown | Anecdotal | |
| Unknown toxicologyNo human safety data; bladder and dependence risks of the class may apply. | Moderate | Unknown | Unconfirmed |